VVOS Company Profile and Key Details

Vivos Therapeutics, Inc. (NASDAQ:VVOS) closed at $1.32 USD, gaining $0.02 (1.54%) from the previous close of $1.30. The stock is currently mid-range between its 52-week high and low $1.08 and $7.95. With a market capitalization of about $7.77 million, Vivos Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~7.02). Key stats such as the average daily volume over the past year has been around 120.44 thousand shares, volume is running light vs its 52-week average. Headquartered in Highlands Ranch, CO, Vivos Therapeutics, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO R. Kirk Huntsman, the company employs approximately 109 people and listed since December 11, 2020. Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.

Vivos Therapeutics, Inc. trades at a P/E ratio of -0.85, slightly below the S&P 500 average, with a price-to-sales ratio of 0.45 and a price-to-book ratio of 5.72 trading at moderately above to book value. The P/FCF stands at -0.54, also below market averages.

Vivos Therapeutics, Inc. has 7.50 million shares outstanding. The public float is 5.43 million shares, elevated short interest at 2.81% of float. This equals 194.29 thousand shares. The short ratio is 1.11 days. Institutional investors hold 15.81% of the float. Insiders own 24.66%.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Our AI price prediction model suggests that Vivos Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.64%, with price expected at $1.14 by April 16, 2026, within a range of $1.08 to $1.20 3-Month Outlook: Projected rise of 44.7%, reaching $1.91 by July 01, 2026, with a range of $1.69 to $2.10. 1-Year Outlook: Projected loss of -91.67%, with price at $0.11 by April 02, 2027, within a range of $0.00 to $0.61.

Vivos Therapeutics, Inc. generated EPS of -$1.97 over the past year. Five-year average earnings growth is 32.77%. The latest quarter delivered EPS of -$0.49. The next quarter is forecast at -$0.48. Next year's EPS is expected at $59.76. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $6.50. The high target offers 430.3% upside. The low target suggests 392.42% downside. The mean target is $6.67. This offers 405.3% upside. Vivos Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 19, 2025, missed forecasts by 7.07%. The prior quarter beat by 103.7%. Over the last six quarters, Apple has recorded several small beats. These include -42.86% in August 14, 2024.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares are flat -2.96% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Vivos Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.85. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.96, suggesting 351.52% upside. Our AI forecast model points to short-term weakness (-13.64% over two weeks), a medium-term rise (44.7% over three months), and a longer-term loss (-91.67% over one year), with expected trading ranges indicating moderate volatility.

Short-term trend indicators are bullishly aligned (SMA20 -7.97%, SMA50 -21.71%, SMA200 -51.89%). The stock’s 14-day RSI is 34.7 (weak momentum), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -81.76% below its high and over 1.86% above its low. Average 10-day trading volume of 87.62 thousand shares is below the 3-month average of 117.66 thousand, indicating normal recent market interest.